Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol. 2014;15:e315-e326.van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol 2014;15:e315-326....
Imatinib, one of the first tyrosine kinase inhibitors (TKIs) to be approved, revolutionized the treatment of chronic myelogenous leukaemia. Other compounds with different spectra of kinase inhibition are currently used to treat renal cell carcinoma, non-small-cell lung cancer and colon cancer. More ...
Tyrosine kinase inhibitors (TKIs) are biologically active compounds that block tyrosine kinases, which are chemical messengers (i.e., enzymes) that control cell growth and division. TKIs have been developed into potent anticancer drugs, but TKIs are also able to inhibit edema in the retina and ...
www.nature.com/scientificreports OPEN received: 15 July 2015 accepted: 04 November 2015 Published: 08 December 2015 Drug-Drug Interaction Potentials of Tyrosine Kinase Inhibitors via Inhibition of UDP- Glucuronosyltransferases Nan Zhang3, Yong Liu4 & Hyunyoung Jeong1,2 Tyrosine kinase ...
At present, receptor tyrosine kinase signaling-related pathways have been successfully mediated to inhibit tumor proliferation and promote anti-angiogenesis effects for cancer therapy. Tyrosine kinase inhibitors (TKIs), a group of novel chemotherapeutic agents, have been applied to treat diverse malignant ...
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of certain forms of cancers, raising hopes for many patients with otherwise unresponsive tumours. While these agents are generally well tolerated, clinical experience with them has highlighted their unexpected association with serious toxic...
ATP-binding cassette (ABC) drug transporters have both physiological and pharmacological importance in humans. They not only protect the cells from xenobiotics, but also alter the pharmacokinetics and toxicity of drugs that are substrates for these trans
A major challenge to improving the benefits of targeted therapies is understanding the molecular mechanisms of acquired resistance to tyrosine kinase inhibitors (TKIs). Enormous efforts have been made to identify activating mutations, particularly those involved in cancer initiation and drug resistance. ...
Despite epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) have shown remarkable efficacy in patients with EGFR-mutant non-small cell lung cancer (NSCLC), acquired resistance inevitably develops, limiting clinical efficacy. We found
Nanoparticle-based drugs delivery systems containing tyrosine kinase inhibitors Currently, new generation drug delivery systems prepared with nanocarriers have replaced conventional drugs in cancer treatment. Nanoparticulate systems are solid colloidal particles with sizes ranging from 10 to 1000 nm that have ...